Launch

Sanofi seeks to revive Kynamro launch

Sanofi seeks to revive Kynamro launch

By

Kynamro's slow start, coupled with competition, has prompted Sanofi to add sales reps.

Sovaldi launch trounces Incivek's

Prescription data shows Gilead's Sovaldi is winning prescriptions at a faster rate than Vertex's Incivek did at launch.

Biogen CEO cautions on Tecfidera EU launch

Biogen CEO cautions on Tecfidera EU launch

By

The MS pill saw rapid uptake in the US last year, but its overseas launch won't be as quick, CEO George Scangos conceded this week at an analyst conference.

As HIV meds mature, Gilead preps for HCV launch

As HIV meds mature, Gilead preps for HCV launch

By

A 15% increase in sales came on the back of HIV franchise meds Stribild and Complera/Eviplera.

Tecfidera sales soar, cannibalize older med

Tecfidera sales soar, cannibalize older med

By

Based on its first three months on market, Tecfidera is one launch that's living up to its hype.

Mixed results underscore orphan launch hurdles

By

Early sales of NPS's Gattex have soared, while those of Protalix's Elelyso have been sluggish, underscoring the challenges of rare-disease launches.

In wake of HCV setback, Vertex to contain marketing spend

By

While a strong launch of CF drug Kalydeco helped to hike the biotech's forecast, hep. C contender VTX-135 was hit with a partial clinical hold.

Navidea deploying MSLs in launch of new diagnostic agent

Navidea deploying MSLs in launch of new diagnostic agent

By

Medical science liaisons will educate nuclear-medicine clinicians as part of the launch of a new Navidea diagnostic agent for use in breast and skin cancer.

Why SGLT-2s may put some spring into pharma spending

Why SGLT-2s may put some spring into pharma spending

Should the FDA give the thumbs-up to J&J diabetes pill Invokana tomorrow, expect a blockbuster US marketing push, says CSD's Jerry Maynor.

Pent-up demand stands to drive Tecfidera, docs say

Pent-up demand stands to drive Tecfidera, docs say

By

Two-fifths of US neurologists polled said they're warehousing MS patients in anticipation of Tecfidera, though pricing worries could dampen sales.

Wishbone team hangs out a new shingle

Wishbone team hangs out a new shingle

By

Medical agency Wishbone was acquired years ago, but the leadership team behind the shop is coming out of retirement with a new venture, dubbed Calcium.

Dendreon calls in air reinforcements for Provenge

Dendreon calls in air reinforcements for Provenge

By

Dendreon is readying a $5 million-per-quarter "targeted" DTC advertising campaign as the company seeks to goose sluggish growth in sales of its prostate cancer treatment Provenge.

Purdue takes to the airwaves with Intermezzo ads

Purdue takes to the airwaves with Intermezzo ads

By

After several years of quiet among prescription sleep aids, Purdue Pharma has issued a wake up call to the category with an ad campaign featuring an adorably memorable anthropomorphic lightbulb.

Santarus loads up on sales reps

By

The company is beefing up its marketing staff, using an iPad-equipped mix of in-house and contracted talent.

BMS's 2013 looking up as Eliquis launch gears up

BMS's 2013 looking up as Eliquis launch gears up

By

Bristol-Myers Squibb issued relatively upbeat guidance for 2013, but much depends on the performance of Eliquis.

Year-end approval clears Eliquis for US launch

Year-end approval clears Eliquis for US launch

By

Eliquis was approved Friday for preventing strokes in patients with nonvalvular atrial fibrillation, becoming the third oral anticoagulant to reach the US market.

Home HIV test maker preps TV ad fusillade, lures Pfizer marketer

By

OraSure, the maker of the recently-approved home HIV test, has hired an experienced consumer marketer from Pfizer to head up the launch as it readies a TV ad campaign.

Transcept, Purdue plan DTC effort to revive sleep-drug launch

By

Facing lower-than-expected demand, Purdue and Transcept are broadening the commercial strategy for Intermezzo to include DTC and a larger selling force.

Sanofi launches Fluzone DTC with prickly-cute creative

Sanofi launches Fluzone DTC with prickly-cute creative

By

Sanofi Pasteur has launched its first consumer advertising for Fluzone Intradermal, featuring a prickly pitch-critter meant to stress the flu vaccine's extra-thin needle.

AstraZeneca launches Brilinta adherence effort

By

AstraZeneca launched a new adherence program for its antiplatelet Brilinta, dubbed Complete the Course.

Boehringer: Pradaxa, Tradjenta launches face 'economic headwind'

By

The family-owned pharma cautioned that early 2012 success doesn't mean the second half will be a breeze.

Vivus in talks to out-license ED drug Stendra

By

Rather than test the waters for faster-than-Viagra drug Stendra, Vivus wants another firm to handle marketing.

Company news: Corcept Therapeutics and Daiichi Sankyo

Corcept Therapeutics said its Cushing's syndrome drug will be launched three weeks earlier than expected.

Judge puts freeze on Merz bid to challenge Botox

By

US District Court Judge Andrew Guilford slammed the breaks on Merz's foray into a market dominated by Botox, siding with Allergan in a case about stealing intellectual property and poaching sales reps.

Company news: WebMD, Wiley-Blackwell and Eli Lilly/Boehringer Ingelheim

WebMD the Magazine is now part of the iPad app world.

Bydureon approval a shot across bow for Victoza

Bydureon approval a shot across bow for Victoza

By

The FDA's go-ahead for Bydureon gives maker Amylin a much-needed win in the GLP-1 market.

No 'pent-up demand' for cancer med Jakafi, Incyte says

By

The launch of new cancer pill Jakafi will require extensive education, said Incyte Pharmaceuticals, owing partly to low awareness levels among doctors.

Incivek's $1 bil. in sales this year would set record for fastest launch, analyst says

By

Vertex's drug for treating hepatitis C virus, Incivek (telaprevir), is on course to smash the previous record for the biggest revenue-generating drug launch ever, says an analyst firm.

Branded Benlysta DTC campaign ready to roll out

By

New online and print DTC advertising targeting US patients with lupus will appear "within weeks," said executives from Human Genome Sciences. Can the campaign revive blockbuster fortunes for Benlysta?

Prolia, Xgeva fall short of analysts' Q3 sales forecasts

By

Amgen's global sales, up 3% in the third quarter, met analyst estimates, but its new denosumab franchise reflected slower growth than expected.

Email Newsletters